RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

被引：35

作者：

Shen, Lin

Kato, Ken

Kim, Sung-Bae

Ajani, Jaffer A.

Zhao, Kuaile

He, Zhiyong

Yu, Xinmin

Shu, Yongqian

Luo, Qi

Wang, Jufeng

Chen, Zhendong

Niu, Zuoxing

Sun, Jong Mu

Lin, Chen-Yuan

Hara, Hiroki

Pazo-Cid, Roberto

Borg, Christophe

Li, Liyun

Tao, Aiyang

Van Cutsem, Eric

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[2] Natl Canc Ctr, Tokyo, Japan

[3] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Fudan Canc Hosp, Shanghai, Peoples R China

[6] Fujian Med Univ, Canc Hosp, Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China

[7] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[8] Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China

[9] Xiamen Univ, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China

[10] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[11] Anhui Med Univ, 2nd Hosp, Hefei, Anhui, Peoples R China

[12] Shandong Acad Med Sci, Dept Med Oncol, Shandong Canc Hosp, Jinan, Peoples R China

[13] Samsung Med Ctr, Seoul, South Korea

[14] China Med Univ Hosp, Taichung, Taiwan

[15] China Med Univ, Taichung, Taiwan

[16] Saitama Canc Ctr, Saitama, Japan

[17] Hosp Univ Miguel Servet, Zaragoza, Spain

[18] Univ Hosp Besancon, Dept Med Oncol, Besancon, France

[19] BeiGene Ltd, Zhongguancun Life Sci Pk, Beijing, Peoples R China

[20] Univ Hosp Gasthuisberg, Leuven, Belgium

[21] Katholieke Univ Leuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4012

引用

页数：2